Skip to main content
SearchLoginLogin or Signup

Review 2: "The Transmission Blocking Activity of Artemisinin-Combination, Non-Artemisinin, and 8-Aminoquinoline Antimalarial Therapies: A Pooled Analysis of Individual Participant Data"

Reviewers raised concerns regarding the study's sample size, the need for clearer statistical measures, justification for their conclusions, and potential improvements in the organization and presentation of the results such as having supplementary results readily available.

Published onJan 04, 2025
Review 2: "The Transmission Blocking Activity of Artemisinin-Combination, Non-Artemisinin, and 8-Aminoquinoline Antimalarial Therapies: A Pooled Analysis of Individual Participant Data"
1 of 2
key-enterThis Pub is a Review of
The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-aminoquinoline antimalarial therapies: a pooled analysis of individual participant data
The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-aminoquinoline antimalarial therapies: a pooled analysis of individual participant data
Description

ABSTRACT Background Interrupting human-to-mosquito transmission is important for malaria elimination strategies as it can reduce infection burden in communities and slow the spread of drug resistance. Antimalarial medications differ in their efficacy in clearing the transmission stages of Plasmodium falciparum (gametocytes) and in preventing mosquito infection. Here we present a combined analysis of six trials conducted at the same study site with highly consistent methodologies that allows for a direct comparison of the gametocytocidal and transmission-blocking activities of fifteen different antimalarial regimens or dosing schedules.Methods and findings Between January 2013 and January 2023, six clinical trials with transmission endpoints were conducted at the Clinical Research Centre of the Malaria Research and Training Centre of the University of Bamako in Mali. These trials tested Artemisinin-Combination Therapies (ACTs), non-ACT regimens and combinations with 8-aminoquinolines. Participants were males and non-pregnant females, between 5-50 years of age, who presented with P. falciparum mono-infection and gametocyte carriage by microscopy. Blood samples were taken before and after treatment for thick film microscopy, infectivity assessments by mosquito feeding assays and molecular quantification of gametocytes. Mixed-effects generalized linear models were fit with individual-specific random effects and fixed effects for time points, treatment groups and their interaction. Models quantified changes in mosquito infection rates and gametocyte densities within treatment arms over time and between treatments. In a pooled analysis of 422 participants, we observed substantial differences between ACTs in gametocytocidal and transmission-blocking activities, with artemether-lumefantrine (AL) being significantly more potent at reducing mosquito infection rates within 48 hours than dihydroartemisinin-piperaquine (DHA-PPQ), artesunate-amodiaquine (AS-AQ) and pyronaridine-artesunate (PY-AS) (p<0.0001). The addition of single low dose primaquine (SLD PQ) accelerated gametocyte clearance and led to a significantly greater reduction in mosquito infection rate within 48-hours of treatment for each ACT, while an SLD of the 8-aminoaquinoline tafenoquine (TQ) showed a delayed but effective response compared to SLD primaquine. Finally, our findings confirmed considerably higher post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ) compared to most ACTs, with a significantly lower relative reduction in mosquito infection rate at day 7 compared to DHA-PPQ, AS-AQ, and AL (p<0.0001). Therefore, adding an SLD PQ to SP-AQ may be beneficial to block malaria transmission in community treatment campaigns.Conclusions We found marked differences among ACTs and single low-dose 8-aminoquinoline drugs in their ability and speed to block transmission. The findings from this analysis can support treatment policy decisions for malaria elimination and be integrated into mathematical models to improve the accuracy of predictions regarding community transmission and the spread of drug resistance under varying treatment guidelines.

RR\ID Evidence Scale rating by reviewer:

  • Reliable. The main study claims are generally justified by its methods and data. The results and conclusions are likely to be similar to the hypothetical ideal study. There are some minor caveats or limitations, but they would/do not change the major claims of the study. The study provides sufficient strength of evidence on its own that its main claims should be considered actionable, with some room for future revision.

***************************************

Review: It is interesting and useful to combine the recent trials of the effect of different ACTs on gametocyte prevalence and density, proportion of infected mosquitoes and mean oocyst density. The number of participants per study was relatively low, so combining them improves the power of the findings. The paper has been carefully compiled with explanations of the similarities and differences between the trials, with useful graphics such as Figure 1 to show when outcomes were assessed. The trials were done in similar fashion with consistent methods for assessing outcomes such as infectivity.  In fact all the graphics used are very clear and show the differences between the ACTs.  There are apparently a large number of supplementary files which I wanted to consult but could not find a link to. 

The results of the comparisons between DHA-PPQ, SP-AQ, PY-AS, AS-AQ and AL are all clear, especially in Fig 6. I don't find it valid to combine all the Non-ACT-PQ and compare with ACT-PQ.  Non-ACT-PQ includes only SP-AQ with PQ (N=20) if I am not mistaken (Table 1).  ACT-PQ includes AL, AL-AQ, DHA-PPQ, AS-AQ and PY-AS with high heterogeneity between their effects (without PQ) and many more participants (N=142). I don't think that you can conclude from this that PQ should be added to 'ACT'. The statement in lines 364 to 366 that "adding a single low dose of PQ ...to any ACT accelerated the clearance of gametocytes and led to significantly greater reduction in mosquito infection rate..." needs more statistical justification. It likely depends on the ACT, but without access to the data on separate ACTs with and without PQ in valid comparisons I cannot assess.  Similarly calling the last graph in Fig 6 "ACT-TQ" is a bit misleading when it is only DHA-PPQ in this group. 

There is so much valuable information in this paper, much of which is apparently in supplementary files. I think it could be split into two or more papers, with the first main findings comparing the ACTs, and the PQ and TQ addition in a separate analysis.  This would allow inclusion of more of the relevant data in the main text, such as the mosquito infection data (lines 296 to 298).

I rate this preprint as 'reliable' because of the strength of the results for the different ACTs (without PQ), despite the concerns about the PQ addition data and the pooling of the different ACTs in this comparison. 

Comments
0
comment
No comments here
Why not start the discussion?